Neod001 Medicine 09 January 2018 Extended indication Primary systemic amyloidosis. Therapeutic value No judgement Total cost Registration phase Unknown Product Active substance Neod001 Domain Metabolism and Endocrinology Reason of inclusion Main indication Metabolic diseases Extended indication Primary systemic amyloidosis. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Prothena Portfolio holder Mechanism of action Unknown Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date Expected Registration 2018 Orphan drug Yes Registration phase Unknown Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume < 8,500 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Orphanet: Prevalence is 1-5 / 10 000. Dit betekent 1.700-8.500 per 17 miljoen inwoners. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks